Tracer library / [177Lu]Lu-pentetreotide

[177Lu]Lu-pentetreotide

Also written as [177Lu]Lu-pentetreotide
Radionuclide
Lu-177
Modality
—
Production route
—
Stage
Clinical research
Syntheses indexed
0
Peptide receptor radionuclide therapy

What it is

Compound class
Radiolabeled somatostatin analogue peptide
Target / mechanism
Somatostatin receptors (SSTRs) PMID 40876985
Clinical application
Peptide receptor radionuclide therapy for unresectable multi-recurrent olfactory neuroblastoma expressing somatostatin receptors PMID 40876985
Theranostic pair
—

Published syntheses

No synthesis has been parsed for this agent yet.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

  1. Survival Outcome for Peptide Receptor Radionuclide Therapy in Olfactory Neuroblastoma.
    2025 · Anticancer Res · Clinical study
  2. Peptide receptor radionuclide therapy in patients with inoperable meningiomas: our experience and review of the literature.
    2014 · Cancer Biother Radiopharm · Clinical study

Need this precursor?We can point you to suppliers for [177Lu]Lu-pentetreotide, or handle the enquiry for you.

Get in touch

Notes

Added at stage 39 (2026-09-27) from a reverse search of the PubMed corpus's own unattached articles (articles that named a real compound not yet in this reference): 3 article(s) found under this name, not yet individually researched. Target/mechanism, clinical application, indications, approval, modality, stage and production route are intentionally left empty. PMIDs: 24811687, 28218348, 40876985. Stage set/updated at stage 39 from PMID 40876985: 'the 3 patients who received PRRT had significantly longer overall survival from the time of diagnosis compared to the 8 patients who did not receive PRRT'.